CWC Advisors LLC. Purchases New Holdings in Haemonetics Co. (NYSE:HAE)

CWC Advisors LLC. purchased a new stake in shares of Haemonetics Co. (NYSE:HAE) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,871 shares of the medical instruments supplier’s stock, valued at approximately $231,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HAE. Quarry LP bought a new position in Haemonetics during the second quarter valued at about $39,000. Covestor Ltd grew its stake in shares of Haemonetics by 184.8% in the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 438 shares during the period. Daiwa Securities Group Inc. bought a new stake in shares of Haemonetics in the 2nd quarter valued at approximately $82,000. Canada Pension Plan Investment Board bought a new stake in shares of Haemonetics in the 2nd quarter valued at approximately $83,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Haemonetics in the 1st quarter valued at approximately $86,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on HAE. Bank of America began coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target on the stock. CL King initiated coverage on Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Citigroup reduced their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. Finally, Barrington Research reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a report on Monday, September 23rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.14.

Haemonetics Price Performance

HAE opened at $75.54 on Friday. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12 month low of $70.74 and a 12 month high of $97.97. The company has a fifty day simple moving average of $75.70 and a 200 day simple moving average of $83.30. The stock has a market cap of $3.87 billion, a P/E ratio of 33.87, a P/E/G ratio of 1.16 and a beta of 0.30.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same quarter in the prior year, the company earned $1.05 EPS. Haemonetics’s quarterly revenue was up 8.0% on a year-over-year basis. On average, research analysts expect that Haemonetics Co. will post 4.57 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.